Course: Navigating Advances in Early Breast Cancer: Improving Access and Equity in Rural and Underserved Settings
CME Credits: 0.00
Released: 2026-01-15
Hormone receptor–positive, human epidermal growth factor receptor 2–negative (HR+/HER2-) is the most common subtype of breast cancer. Endocrine therapy is the primary treatment option, but resistance remains common. Recently, therapies such as CDK4/6 inhibitors, PARP inhibitors, and novel endocrine therapies have been shown to improve outcomes in patients with HR+/HER2- early breast cancer. However, individuals residing in rural and underserved communities often face significant barriers such as clinician shortages, limited access to various therapies, and geographic barriers, leading to disparities in care and worse outcomes. This on-demand CME/CE activity will review current and emerging therapies for this population, including the latest efficacy and safety data and current guidelines on biomarker and genetic testing. Expert faculty will also share collaborative strategies to improve early breast cancer care and management in rural and underserved settings. This enduring activity is a recorded session from Oncology Congress that took place on October 25, 2025.
Upon completion of this activity, participants should be better able to:
View Full Course